FDAnews
www.fdanews.com/articles/84563-axonyx-reports-phenserine-study-data

AXONYX REPORTS PHENSERINE STUDY DATA

February 14, 2006

Axonyx has reported a significant reduction in the plasma levels of beta-amyloid 1-42 (A beta-42) in healthy human subjects treated with Phenserine for 35 days. This additional analysis was recently completed as part of the program to identify a partner for the further development of Phenserine.

Six healthy men and six healthy women were enrolled in this multiple-dose Phase I study. Subjects were treated with Phenserine 10mg twice daily for 28 days and Phenserine 15mg twice daily for an additional week. Plasma samples were collected on Days 1, 28, 29, and 35, with plasma A beta-42 assessments available for 11 subjects. Samples were collected in accordance with a pre-defined pharmacokinetic sampling schedule.